10-K: Cue Biopharma Navigates Financial Hurdles, Advances Autoimmune Pipeline

Cue Biopharma reports recurring losses and going concern doubt, while advancing its autoimmune pipeline with CUE-401 nearing IND filing and CUE-501 licensed to Boehringer Ingelheim, alongside oncology asset licensing.

Summary

• Cue Biopharma is a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases using its Immuno-STAT platform.
• The company reported a net loss of $26.602 million for the fiscal year ended December 31, 2025, an improvement from $40.674 million in 2024.
• Collaboration revenue significantly increased to $27.466 million in 2025 from $9.287 million in 2024, driven by new agreements.
• Cash and cash equivalents stood at $27.1 million as of December 31, 2025, with projected funding into the first quarter of 2027.
• CUE-401, a lead preclinical candidate for autoimmune diseases, is preparing for an IND application in Q2 2026, with Phase 1 human safety data expected in H2 2026.
• CUE-501, for autoimmune B cell depletion, was licensed to Boehringer Ingelheim International GmbH in April 2025, including an upfront payment of $10.1 million (net of withholding taxes) and potential milestones up to $345 million.
• The CUE-100 series (oncology assets CUE-101 and CUE-102) was licensed to ImmunoScape Pte. Ltd. in November 2025, generating $9.5 million (net of withholding taxes) upfront and an additional $5.0 million by the first anniversary, plus 40% equity in ImmunoScape.
• The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and the need for additional capital.
• Nasdaq listing compliance is an ongoing issue, with an extension until May 11, 2026, and a proposed reverse stock split to be voted on by stockholders on April 13, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a high-risk, early-stage biopharma with significant financial challenges, including going concern doubt and Nasdaq compliance issues. While recent collaborations provide some capital and validation, the path to profitability remains long and uncertain, heavily reliant on future financing and clinical success.

Positives

• Collaboration revenue increased significantly to $27.466 million in 2025 from $9.287 million in 2024, primarily due to new licensing agreements.
• Net loss decreased to $26.602 million in 2025 from $40.674 million in 2024, indicating improved financial performance.
• Successful licensing of CUE-501 to Boehringer Ingelheim International GmbH, including a $10.1 million upfront payment and potential milestones up to $345 million.
• Successful licensing of CUE-100 series to ImmunoScape Pte. Ltd., including $9.5 million upfront, an additional $5.0 million, and a 40% equity stake in ImmunoScape.
• CUE-401, a lead autoimmune candidate, is nearing IND application filing in Q2 2026, with human safety data anticipated in H2 2026.
• Cash used in operating activities decreased by $14.6 million in 2025 compared to 2024.
• The company's Immuno-STAT platform is described as differentiated, offering potential competitive advantages in targeting disease-relevant T cells without systemic toxicity.

Negatives

• Recurring losses from operations and an accumulated deficit of $368.5 million as of December 31, 2025.
• Substantial doubt exists regarding the ability to continue as a going concern, with current funds projected to last only into Q1 2027.
• No history of generating commercial revenue and no FDA-approved or commercialized products to date.
• Dependence on substantial additional financing, which may be difficult to obtain on acceptable terms and could lead to significant stockholder dilution or relinquishing rights to technologies.
• Nasdaq minimum bid price deficiency, with a potential delisting if compliance is not regained by May 11, 2026, despite a proposed reverse stock split.
• Significant reliance on third parties for clinical trials and manufacturing, which introduces risks of delays, quality issues, and contractual breaches.
• Exclusivity provisions in collaboration agreements (e.g., with BI for B cell depletion) restrict the company's own R&D activities in certain areas.
• The company has limited experience in conducting clinical trials and no history of commercializing biologic products.

Risks

• Recurring losses from operations raise substantial doubt regarding the ability to continue as a going concern.
• Inability to obtain additional funding on acceptable terms could force delays, reductions, or discontinuation of product development programs, or lead to dissolution and liquidation.
• No history of generating commercial revenue and may never achieve or maintain profitability.
• Substantial dependence on the success of drug product candidates, which require significant additional R&D and clinical testing before regulatory approval.
• Limited experience in conducting clinical trials and no history of commercializing biologic products, making future viability difficult to evaluate.
• Success in preclinical studies or early clinical trials may not be indicative of results obtained in later trials.
• Inability to establish or maintain collaborations or strategic alliances, or such relationships not providing expected benefits.
• Failure to identify additional drug product candidates or incorrect prioritization decisions due to limited resources.
• Significant competition from other biotechnology and pharmaceutical companies with greater resources and experience.
• Reliance on third parties to conduct clinical trials and manufacture drug supplies, posing risks of delays, quality issues, and contractual breaches.
• Inability to protect intellectual property (patents, trade secrets) could adversely affect financial condition and competitive position.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• The marketing approval process is expensive, time-consuming, and uncertain, potentially preventing or delaying commercialization.
• Subject to regulation in respect of research and federal funding, including potential march-in rights by the U.S. government.
• Failure to obtain marketing approval in foreign jurisdictions would impair revenue generation.
• Inability to maintain orphan drug designation benefits, including market exclusivity.
• Competition from biosimilars approved through abbreviated regulatory pathways.
• Expedited review programs (Fast Track, Breakthrough Therapy, Priority Review) do not assure faster approval or approval at all.
• Potential for significant adverse events, toxicities, or side effects in clinical trials not seen in preclinical studies.
• Ongoing regulatory obligations and continuing review post-approval could require substantial resource expenditure and limit product marketing.
• Failure to comply with regulations restricting promotion of products for unapproved uses could lead to penalties.
• Disruptions at the FDA and other government agencies (e.g., funding cuts, government shutdowns) could hinder development and approval.
• Relationships with healthcare providers, physicians, and third-party payors are subject to anti-kickback, fraud and abuse, and other healthcare laws.
• Commercial third-party payors or government payors failing to provide coverage or adequate reimbursement would harm revenue and profitability.
• Recently enacted and future legislation (e.g., IRA, OBBBA) may increase costs and affect pricing.
• Compliance with global privacy and data security requirements (e.g., GDPR, CCPA) could result in additional costs and liabilities.
• Employees, principal investigators, consultants, and commercial partners may engage in misconduct.
• War, terrorism, other acts of violence, or natural/manmade disasters may affect markets, patients, and R&D resources.
• Changes in tax laws or their implementation/interpretation could adversely affect business and financial condition.
• Stock price volatility and potential for substantial losses for stockholders.
• Failure to regain compliance with Nasdaq listing requirements could lead to delisting.
• Securities litigation is expensive and could divert management attention.
• Inability to use net operating loss carryforwards and R&D tax credits due to ownership changes or regulatory changes.
• Significant costs and management time devoted to public company compliance obligations.
• Charter documents and Delaware law may inhibit a takeover.
• Exclusive forum provision in Certificate of Incorporation could limit stockholders' ability to obtain a favorable judicial forum.
• Inability to implement and maintain effective internal control over financial reporting.
• Sales of a significant number of outstanding shares could drop the market price.
• Large number of outstanding warrants could dilute common stock and make future equity raises difficult.

Future Outlook

The company anticipates filing an IND application for CUE-401 in the second quarter of 2026 and expects human safety data from its Phase 1 trial in the second half of 2026. It plans to continue seeking additional strategic alliances and collaborations to complement its development and commercialization efforts. The company expects its expenses to increase with ongoing R&D, clinical trials, and public company operations, necessitating substantial additional financing.

Management Comments

• We believe our Immuno-STAT platform holds the promise of producing drug product candidates with the potential of establishing new standards of care in the treatment of autoimmune and inflammatory diseases.
• We believe these results [for CUE-401], along with advances in the manufacturing of CUE-401, have substantially reduced the risk profile for the development of this program, and we have selected a lead candidate molecule.
• We believe this [CUE-401] could represent a potential breakthrough as a new standard of care in multiple high-value autoimmune disease indications.
• We believe the preclinical data generated to date for CUE-401 and the CUE-500 series demonstrates the intended mechanistic effect of these novel approaches for the potential treatment of autoimmune disease, and each represent potential breakthrough therapeutic opportunities for significant patient populations and potential near-term value creation opportunities for our shareholders.
• We believe that our science is derisked with clinical tolerability and activity from our Phase 1 clinical trials of CUE-101 and CUE-102, with the potential for significant market opportunities.
• As a result of our insights and learnings from our growing body of supportive data, we believe our corresponding strategic plans position us well to optimize shareholder value.
• We intend to maximize this value by focusing on the development of CUE-401, for which we are preparing to file an IND application in the second quarter of 2026.
• We expect research and development expenses to remain consistent in future periods.
• We expect general and administrative expenses to remain consistent in future periods as we continue to incur expenses related to our operation as a public company.
• Based on our current operating plans, we believe we will have sufficient funds to meet our obligations into the first quarter of 2027.
• We expect to finance our future cash needs through a combination of equity offerings, collaborations, and other strategic alliances.

Industry Context

StockSavvy.ai notes that Cue Biopharma's Immuno-STAT platform, designed for selective T-cell modulation, positions it within a competitive landscape of cytokine-based therapies and regulatory T cell therapies. The company's strategic shift to prioritize autoimmune programs (CUE-401, CUE-500 series) aligns with a growing focus on precision immunotherapies to minimize off-target effects, a key challenge in traditional approaches. The licensing deals with Boehringer Ingelheim and ImmunoScape reflect a common industry strategy for clinical-stage biopharma companies to de-risk and fund pipeline development through partnerships, especially for oncology assets which often require significant capital and specialized expertise. The regulatory environment, particularly regarding accelerated approval pathways and diversity action plans, continues to evolve, impacting drug development timelines and costs across the industry.

Comparison to Industry Standards

• The Immuno-STAT platform aims to offer a differentiated approach by targeting disease-relevant T cells without inducing systemic toxicity, which is a common challenge in traditional immunotherapies.
• The company competes with major pharmaceutical and biotechnology companies like Amgen, Bristol-Myers Squibb, Merck & Co., Nektar Therapeutics, Sanofi S.A., TRex Bio, and RegCell in cytokine-based therapies.
• In the regulatory T cell therapies space, competitors include Coya Therapeutics, Quell Therapeutics, EVOQ Therapeutics, and Sonoma Biotherapeutics. Many of these competitors possess significantly greater financial, technical, and human resources.
• The company believes its CUE-401, a masked TGF-b and IL-2 molecule, provides a superior competitive advantage and differentiation as a potentially first-in-class therapy designed to rebalance Treg and effector cell ratios, addressing the underlying mechanism of autoimmune disease.
• The CUE-500 series is positioned as significantly differentiated from other competing approaches such as bifunctional antibody drug conjugates, pan-T cell engagers, IL-2 muteins, TNFR2 agonists, and CAR-T therapies for targeted cell depletion.
• The licensing of CUE-100 series to ImmunoScape for a "Seed-and-Boost immunotherapy" aims to overcome limitations of existing cell therapies, suggesting an ambition to set a new standard of care with superior anti-tumor activity, durable T cell persistence, and product scalability.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any pending legal proceedings that are believed to have a material adverse effect on the business or financial conditions.

Related Party Transactions

• No related party transactions were entered into during the years ended December 31, 2025 and 2024.
• No related party balances existed as of December 31, 2025 and 2024.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity offerings. Risk of delisting from Nasdaq could negatively impact liquidity and share price. Potential for long-term value creation if pipeline candidates succeed and collaborations yield significant returns.
• Employees: Reduction in headcount led to a decrease in employee compensation. Incentive plans (stock options) are in place to attract, retain, and motivate.
• Customers/Patients: Potential for new therapeutic options in autoimmune and oncology diseases if drug candidates achieve regulatory approval.
• Collaborators (BI, IMSCP): Continued strategic partnerships are crucial for funding and advancing pipeline, indicating mutual benefit and shared risk.
• Creditors: Loan principal balance with Silicon Valley Bank was fully paid off in December 2025, reducing debt obligations.

Next Steps

• File an Investigational New Drug (IND) application for CUE-401 in the second quarter of 2026.
• Initiate a Phase 1 trial for CUE-401 (single ascending dose and multiple ascending dose in healthy volunteers).
• Anticipate receiving human safety data for CUE-401 starting in the second half of 2026.
• Seek additional strategic alliances or collaborations for drug product candidates.
• Stockholders to vote on a reverse stock split proposal at the 2026 Annual Meeting on April 13, 2026, to regain Nasdaq compliance.
• Continue to evaluate available options to regain Nasdaq compliance by May 11, 2026.
• ImmunoScape Pte. Ltd. to develop CUE-100 series molecules for oncology indications.
• Boehringer Ingelheim International GmbH to research, develop, manufacture, and commercialize CUE-501.
• The company will need to raise substantial additional capital to fund future operations beyond Q1 2027.

Key Dates

Recommendation

The company is in a high-risk, high-reward stage. While the significant increase in collaboration revenue and the advancement of pipeline candidates (CUE-401 nearing IND, CUE-501 and CUE-100 series licensed) are positive developments, the recurring losses, substantial doubt about going concern, and the ongoing Nasdaq minimum bid price compliance issue present considerable financial and operational risks. The stock is speculative, and while there's potential for future growth, the immediate financial uncertainties warrant a "hold" rather than a "buy" or "sell" for a seasoned investor, pending clearer resolution of financial stability and clinical milestones.

Keywords

Biopharmaceutical, Immuno-STAT, Autoimmune Disease, Oncology, CUE-401, CUE-501, CUE-100 Series, Boehringer Ingelheim, ImmunoScape, SEC Filing, 10-K, Clinical Stage, Preclinical Development, IND Application, Regulatory Approval, Going Concern, Nasdaq Listing, Capital Raise, Intellectual Property, Biologics, T-cell modulation, Drug Development, Licensing Agreement, Financial Performance